钠-葡萄糖共转运蛋白2抑制剂治疗心力衰竭的机制及临床研究进展  

Mechanism and Clinical Research Progress of Sodium-glucose Cotransporter 2 Inhibitor in Treatment of Heart Failure

作　　者：卢容宏 王瑜[1] LU Ronghong;WANG Yu(Department Three of Comprehensive Internal Medicine,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China)

机构地区：[1]新疆医科大学第一附属医院综合内三科,乌鲁木齐830054

出　　处：《医学综述》2023年第6期1163-1169,共7页Medical Recapitulate

基　　金：新疆维吾尔自治区天山青年计划项目(2020Q039)。

摘　　要：2型糖尿病(T2DM)和心力衰竭(HF)均为全身性、复杂的慢性疾病,近年来患病率持续上升,且这两种疾病往往共存。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)是一类降糖药物,主要包括达格列净、恩格列净、卡格列净、埃格列净,已明确具有心脏保护作用。最新HF管理指南推荐达格列净和恩格列净作为射血分数降低的HF患者的一线治疗。然而SGLT2i的心脏保护作用尚未完全阐明,目前认为与血流动力学、代谢学、离子稳态、抗炎症、抗纤维化、抗氧化应激相关。阐明SGLT2i心功能保护作用机制可为HF的治疗提供新方向。Type 2 diabetes mellitus(T2DM)and heart failure(HF)are both systemic and complex chronic diseases with increasing prevalence in recent years,and the two diseases often coexist.Sodium-glucose cotransporter 2 inhibitor(SGLT2i)is a type of hypoglycemic agents,mainly including dapagliflozin,empagliflozin,canagliflozin,and ertugliflozin,which have been proven to have cardioprotective effects.The latest HF management guidelines recommend dapagliflozin and empagliflozin as the first-line treatment for HF patients with reduced ejection fraction.However,the cardiac protective effect of SGLT2i has not been fully elucidated and is currently believed to be related to hemodynamics,metabolism,ion homeostasis,anti-inflammation,anti-fibrosis,and anti-oxidative stress.Elucidation on the protective mechanism of SGLT2i on cardiac function,can provide a new direction for the treatment of HF.

关 键 词：心力衰竭 2型糖尿病 钠-葡萄糖协同转运蛋白2抑制剂 心脏保护 

分 类 号：R541.6[医药卫生—心血管疾病]